RxDoctor Payments Data

Henry Altszuler, MD

Cardiovascular Disease · Metuchen, NJNPI 1104818186

Payments from drug & device makers

$260in general payments, 2019–2025

Across 20 payments — averaging $12.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$132
  • Pfizer$62
  • E.r. Squibb & Sons, L.L.C.$28
  • Amarin Pharma, Inc.$13
  • Amgen$12
  • Irhythm Technologies, Inc.$12

What the payments were for

  • Food & beverage$260100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$260 in reported general payments places this provider in the 10th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$223,194
Medicare patients
1,065
Services billed
2,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban456$535,393
XareltoRivaroxaban161$187,057
EntrestoSacubitril/Valsartan109$141,199
MultaqDronedarone Hcl60$78,198
Repatha SureclickEvolocumab43$41,878
JardianceEmpagliflozin29$41,596
Praluent PenAlirocumab19$15,370
FarxigaDapagliflozin Propanediol13$11,922
Metoprolol Succinate606$8,896
BrilintaTicagrelor11$8,877
Atorvastatin Calcium585$7,599
Rosuvastatin Calcium513$6,536
VascepaIcosapent Ethyl11$6,009
PradaxaDabigatran Etexilate Mesylate20$5,602
Icosapent Ethyl19$5,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$535,393456 claims
Johnson & JohnsonXarelto$132$187,057161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Metuchen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →